Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy

British Journal of Anaesthesia

Volumn 113, Issue 1, 2014, Pages 148-156

  Niesters, M ^a   Proto, P L ^a   Aarts, L ^a   Sarton, E Y ^a   Drewes, A M ^b   Dahan, A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

chronic pain, diabetic polyneuropathy; conditioned pain modulation; morphine; neuropathic pain, offset analgesia; pain, tapentadol

Indexed keywords

PLACEBO; TAPENTADOL;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; CONDITIONED PAIN MODULATION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; FEMALE; HEAT; HUMAN; MALE; NEUROPATHIC PAIN; NOCICEPTION; OFFSET ANALGESIA; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT RESPONSE;

CHRONIC PAIN, DIABETIC POLYNEUROPATHY; CONDITIONED PAIN MODULATION; MORPHINE; NEUROPATHIC PAIN, OFFSET ANALGESIA; PAIN, TAPENTADOL;

AGED; ANALGESICS, OPIOID; CHRONIC PAIN; DELAYED-ACTION PREPARATIONS; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURAL PATHWAYS; NOCICEPTION; PAIN MEASUREMENT; PHENOLS; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 84904014567     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeu056     Document Type: Article

References (43)

1. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120: 3779-87
2. King CD, Wong F, Currie T, et al. Deficiency in endogenous modulation of prolonged heat pain in patients with irritable bowel syndrome and temporomandibular disorder. Pain 2009; 143: 172-8
3. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997; 13: 189-96
4. Olesen SS, Brock C, Krarup AL, et al. Descending inhibitory pain modulation is impaired in patients with chronic pancreatitis. Clin Gastroenterol Hepatol 2010; 8: 724-30
5. Seifert F, Kiefer G, DeCol R, Schmelz M, Maihofner C. Differential endogenous pain modulation in complex-regional pain syndrome. Brain 2009; 132: 788-800
6. Tzschentke TM, Christoph T, Kogel B, et al. (2)-(1R, 2R)-3-(3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007; 323: 265-76
7. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 2010; 14: 781-3
8. SchröderW, Vry JD, Tzschentke TM, Jahnel U, Christoph T. Differential contribution of opioidandnoradrenergicmechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010; 14: 814-21
9. Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol HCl, analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future 2006; 31: 1053-61
10. Suzan E, Midbari A, Treister R, et al. Oxycodone alterstemporal summation but not conditioned pain modulation: preclinical findings and possible relations to mechanisms of opioid analgesia. Pain 2013; 154: 1413-8
11. Steigerwald I, Muller M, Kujawa J, Balblanc JC, Calvo-Alen J. Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an openlabel, phase 3b study. J Pain Res 2012; 5: 121-38
12. Arendt-Nielsen L, Andresen T, Malver LP, et al. A double-blind, placebo-controlled study on the effect of buprenorphine and fentanyl on descending pain modulation: a human experimental study. Clin J Pain 2012; 28: 623-7
13. Niesters M, Aarts L, Sarton E, Dahan A. Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo-controlled cross-over proof-of-concept study. Br J Anaesth 2013; 110: 1010-6
14. Niesters M, Dahan A, Swartjes M, et al. Effect of ketamine on endogenous pain modulation in healthy volunteers. Pain 2011; 152: 656-63
15. Yarnitsky D, Arendt-Nielsen L, Bouhassira D, et al. Recommendations on terminology and practice of psychophysical DNIC testing. Eur J Pain 2010; 14: 339
16. Yarnitsky D, Crispel Y, Eisenberg E, et al. Prediction of post-operative pain: pre-operative DNIC testing identifies patients at risk. Pain 2008; 138: 22-8
17. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 2012; 153: 1193-8
18. Grill JD, Coghill RC. Transient analgesia evoked by noxious stimulus offset. J Neurophysiol 2002; 87: 2205-8
19. Niesters M, Hoitsma E, Sarton E, Aarts L, Dahan A. Offset analgesia in neuropathic pain patientsandeffect of treatment withmorphine and ketamine. Anesthesiology 2011; 115: 1063-71
20. Rolke R, Baron R, Maier CT, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 2006; 123: 231-43
21. Tzschentke TM, Folgering JH, Flik G, De Vry J. Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysis. Neurosci Lett 2012; 507: 151-5
22. Bingel U, Tracey I. Imaging CNS modulation of pain in humans. Physiology (Bethesda) 2008; 23: 371-80
23. Frampton JE. Tapentadol immediate release: a reviewof its use in the treatmentofmoderatetosevereacutepain. Drugs2010;70: 1719-43
24. Hoy SM. Tapentadol extended release in adults with chronic pain. Drugs 2012; 72: 375-93
25. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin 2011; 27: 151-62
26. Steigerwald I, Muller M, Davies A, et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an openlabel, phase 3b study. Curr Med Res Opin 2012; 28: 911-36
27. Millan MJ. Descending control of pain. Prog Neurobiol 2002; 66: 355-474
28. De Felice M, Sanoja R, Wang R, et al. Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. Pain 2011; 152: 2701-9
29. Eippert F, Bingel U, Schoell ED, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 2009; 63: 533-43
30. Yilmaz P, Diers M, Diener S, et al. Brain correlates of stress-induced analgesia. Pain 2010; 151: 522-9
31. Brock C, Olesen SS, Valeriani M, Arendt-Nielsen L, Drewes AM. Brain activity in rectosigmoid pain: unraveling conditioning pain modulatory pathways. Clin Neurophysiol 2012; 123: 829-37
32. Moont R, Crispel Y, Lev R, Pud D, Yarnitsky D. Temporal changes in cortical activation during conditioned pain modulation (CPM), a LORETA study. Pain 2011; 152: 1469-77
33. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. Pain 2003; 101: 155-65
34. Lautenbacher S, Kunz M, Burkhardt S. The effects of DNIC-type inhibitionon temporalsummation compared to single pulse processing: does sex matter? Pain 2008; 140: 429-35
35. Ginosar Y, Riley ET, Angst MS. Analgesicandsympathicolyticeffectsof low-dose intrathecal clonidine compared with bupivacaine: a dose- response study in female volunteers. Br J Anaesth 2013; 111: 256-63
36. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010; 30: 489-505
37. Bunyak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. ExpOpin Pharmacother 2010; 11: 1787-804
38. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011; 11: 33-41
39. O'Conner AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122: S22-32
40. Derbyshire SW, Osborn J. Offset analgesia is mediated byactivation in the region of the periaqueductal grey and rostral ventromedial medulla. Neuroimage 2009; 47: 1002-6
41. Darian-Smith J, Johnson KO, LaMotte C, et al. Warm fibers innervating palmar and digital skin of the monkey: responses to thermal stimuli. J Neurophysiol 1979; 42: 1297-315
42. Martucci KT, Eisenach JC, Tong C, Coghill RC. Opioid-independent mechanisms supporting offset analgesia and temporal sharpening of nociceptive information. Pain 2012; 153: 1232-43
43. Naugle KM, Cruz-Almeida Y, Fillingim RB, Riley JL III. Offset analgesia is reduced in older adults. Pain 2013; 154: 2381-7